Sarepta Therapeutics appoints Michael Chambers and Kathryn

CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointments of Michael Chambers and Kathryn Boor, Ph.D., to its board of directors. Both Mr. Chambers and Dr. Boor bring distinct and invaluable experience to Sarepta’s Board of Directors that will help guide the company in its mission to change the course of life-threatening rare diseases.

“We are thrilled to welcome two new board members whose participation will help realize Sarepta’s strategic vision to create transformative therapies for patients with rare diseases,” said Kathleen Behrens, Ph. .D., president of the Sarepta board of directors. .

“Mr. Chambers’ appointment brings tremendous leadership in biosciences and entrepreneurship, as well as deep expertise in areas of fundamental importance to innovators in genetic medicine. Dr. Boor, in addition to his scientific and academic qualifications, is an expert in environment, sustainability and governance, a topic of significant importance to Sarepta,” said Doug Ingram, President and CEO of Sarepta. “These new appointments add to the diversity of experience and perspective within of our Board of Directors, providing exceptional leadership as we work with the utmost urgency to bring innovative genetic medicines to patients.”

Mr. Chambers co-founded Aldevron, based in Fargo, ND, in 1998, and served as its chief executive officer for more than 20 years before becoming executive chairman of the board of directors until 2021, when Aldevron was acquired. for $9.6 billion. As founder, Chambers oversaw the growth of Aldevron into a world-class service organization, specializing in nucleic acid and protein production, antibody development and custom services with operations in the United States. and in Europe. Chambers currently serves on the board of Calviri, Inc.

In 2018, Chambers was named one of the “100 Most Intriguing Entrepreneurs” by Goldman Sachs. He earned his BS in Biotechnology, Microbiology and Chemistry from North Dakota State University.

Dr. Boor is Dean of the Graduate School and Vice Provost for Graduate Education at Cornell University. Previously, Dr. Boor served as Dean Ronald P. Lynch of the College of Agriculture and Life Sciences (CALS) at Cornell. She earned a bachelor’s degree in food science from Cornell University, a master’s degree in food science from the University of Wisconsin, and a Ph.D. in microbiology from the University of California, Davis. She joined the Cornell Food Science department as an assistant professor in 1994, became its first female tenured faculty member in 2000, and led the department from 2007 to 2010.

Dr. Boor serves on the board of directors of Seneca Foods Corporation, International Flavors and Fragrances, the United States-Israel Binational Agricultural Research and Development Fund (BARD), and the Foundation for Food Research and agriculture (FFAR). She serves on the Scientific Advisory Board of the United States Food and Drug Administration and the Regional Economic Development Board for Southern New York State.

About Sarepta Therapeutics
Sarepta has an urgent mission: to develop precision genetic medicine for rare diseases that devastate lives and shorten futures. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMD) and currently have over 40 programs in various stages of development. Our extensive pipeline is driven by our cross-platform precision genetic medicine engine in gene therapy, RNA and gene editing. For more information, visit or follow us on Twitter, LinkedIn, Instagram and Facebook.

Publication of information on the Internet
We regularly post information which may be important to investors in the “For Investors” section of our website at We encourage investors and potential investors to periodically check our website for important information about us.

Forward-looking statements
This press release contains forward-looking statements. All statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes”, “anticipates”, “plans”, “expects”, “will”, “intends”, “potential”, “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements related to Sarepta’s mission to change the course of life-threatening rare diseases and the potential benefits of the addition of Dr. Boor and Michael Chambers to Sarepta’s Board of Directors.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control. Known risk factors include, among others: potential limitations in the Company’s financial and other resources, manufacturing limitations which may not be anticipated or resolved in a timely manner, and regulatory, court or agency decisions, such as that decisions of the United States Patent and Trademark Office regarding patents covering the product candidates; and risks identified under “Risk Factors” in Sarepta’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and other documents filed with the SEC by the Company which you are encouraged to review.

Any of the foregoing risks could have a material adverse effect on the Company’s Sarepta business, results of operations and common share price. For a detailed description of the risks and uncertainties facing Sarepta, we encourage you to consult the filings with the SEC by Sarepta. We caution investors not to place significant reliance on any forward-looking statements contained in this press release. Sarepta undertakes no obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law.

Source: Sarepta Therapeutics, Inc.

Investor contacts:
Ian Estepan, 617-274-4052
[email protected]

Media Contact:
Tracy Sorrentino, 617-301-8566
[email protected]

Comments are closed.